Agenus Announced Sunday, Phase 2 NEOASIS Data At ESMO Showing 72% Of Locally Advanced dMMR Colon Cancer Patients Had No Cancer Remaining At Surgery After 6 Weeks Of BOT+BAL; 83% Achieved Major Pathologic Response, Meeting Primary Endpoint
Share
Why It Matters
Agenus showed that its cancer medicine worked well in early testing. When patients took it before surgery, most had very good results.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.